RPA1 and cancer: Remarkably, ALT cancers were shown to be hypersensitive to ATR inhibition: Flynn et al., by exploiting the fact that ALT cancers lack ATRX (the chromatin remodeller), showed the inability of TERRA to displace RPA from the telomeres following replication and, hence, to silence ATR activation [147].